FDA rejects Pharmacyclics cancer drug; stock plunges
Shares of Sunnyvale-based Pharmacyclics plunged more than 26 percent Monday - the fourth-biggest drop in its history - after federal regulators refused to approve its drug Xcytrin to treat patients whose lung cancer has spread to their brain.
This entry was posted on Tuesday, December 25th, 2007 at 9:42 am and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.